I We have used the term 'chorea' to denote unpredictable, rapid non-purposive muscular jerks of face, tongue, and limbs (which occur at rest and interrupt voluntary activity), and 'dystonia' to denote abnormal sustained muscular contractions which, if continued, result in the maintenance of typically dystonic postures, and if spasmodic, cause slow movements into such dystonic postures. We have avoided the terms 'athetosis' and 'choreoathetosis' as we believe them to be confusing. 'Asterixis' is used to describe irregular postural lapses and subsequent corrections, developing after a latent period, during sustained posture against gravity-for example, of the outstretched hands.
(Accepted 18 August 1976.) dyskinesia with distal chorea of the limbs and dystonic spasms ofaxial and limb muscles. This syndrome has occurred only when DPH is administered in doses causing toxic plasma levels and usually remits when the dose is reduced. The dyskinesias produced by DPH are reminiscent of those provoked by phenothiazine or other neuroleptic drugs, suggesting a similar cause.
CASE HISTORIES (Table 2) CASE 1: ASTERIXIS AND CEREBELLAR SYNDROME DUE TO 
PHENOBARBITONE INTOXICATION
This patient was a 51 year old woman, working as a packer, who had suffered idiopathic grand mal seizures without aura since the age of 17 years. Her seizures has always been difficult to control in spite of taking regular anticonvulsant therapy for 24 years. For the previous 12 months she had been taking DPH 300 mg/day, phenobarbitone 60 mg/day, primidone 500 mg/day, and diazepam 15 mg/day.
She was referred with an episode of drowsiness, unsteadiness, and 'shakiness' of her hands. A similar episode had occurred six months previously and had lasted for three to four weeks.
On examination she was of below normal intelligence, with a childish personality. She showed a mild dysarthria, phasic nystagmus on lateral gaze, and a gait ataxia. 395 ,umol/l (94 pg/ml), DPH 29 ,tmol/l (7 jpg/ml). The dose of phenobarbitone was decreased to 60 mg/day and within two days the asterixis had disappeared to be followed shortly by marked improvement in the gait ataxia and nystagmus. One week later he was symptom free and serum phenobarbitone was 166,Fmol/l (40 pg/ml) and DPH 46 ,smol/l (11.5 ,sg/ml). She agreed to be readmitted and was subsequently rechallenged with DPH 300 mg/day. The orofacial dyskinesia and asterixis returned without other signs of intoxication and the serum DPH level rose above the therapeutic range to 104 pmol/I (26 jig/ml).
Biochemical screening and liver function tests were normal.
Therapy was changed to carbamazepine 300 mg/day on which she was well but continued to have occasional minor seizures. The dose was increased to 600 mg/day but she again developed minor asterixis, with a serum level of 25 ,umol/l (5.4 ,g/ml). Subsequent reduction to 400 mg/day resulted in a disappearance of the asterixis, the serum level falling to 5 Itmol/l (1.5 jug/ml). Among our patients, asterixis was the commonest dyskinesia seen, occurring in cases 1-5. Asterixis has also been described in four other cases reported in the literature and may have been present in two other patients (Table 1) . Spontaneous myoclonic jerks were associated with asterixis in at least two and possibly four of these reported cases.
An orofacial dyskinesia was observed in two of our patients (cases 4 and 5) and similar dyskinesias involving the mouth, jaw and tongue have been reported in 11 other patients (Table 1) . Chorea of the limbs was seen in cases 6 and 7 and has been reported in 12 other patients. (We have taken reports of 'choreoathetosis' to indicate significant chorea) ( Table 1) .
Dystonic movements andpostures clearly related to anticonvulsant intoxication were observed in cases 5 and 6 and may have been precipitated by such intoxication in two others (cases 7 and 8). In case 8, the addition of sulthiame may have induced DPH intoxication (Houghton and Richens, 1974) . Obvious dystonia has been reported in nine other cases (Table 1) .
These dyskinesias have been accepted as rare manifestations of anticonvulsant toxicity. However, we are impressed by the frequency with which we have observed such disorders, all the cases reported here having been seen over an 18 month period.
DRUGS RESPONSIBLE
Asterixis Sometimes associated with spontaneous myoclonic jerks, asterixis has been precipitated by intoxication with DPH, primidone, phenobarbitone, and carbamazepine, in our material, and by DPH in those cases reported in the literature. Orofacial dyskinesias, chorea, and dystonia These have been precipitated only by DPH, with the single exception of the patient reported by Kirschberg (1975) in whom the addition of ethosuximide to DPH appeared reponsible.
Where blood anticonvulsant levels were recorded, dyskinesias due to DPH occurred with plasma levels of 106 to 368 pmol/l ,tg/ml). Nystagmus and other signs of cerebellar toxicity usually appear when the plasma DPH level exceeds 80 ,umol/l (Buchthal and Lennox-Buchthal, 1972a ). In the two cases of asterixis caused by phenobarbitone, the plasma level was 269 ,umol/l (64 Htg/ml) and 395 ,tmol/l (94 ,g/ml) (upper limit of therapeutic range is about 150 ,umol/l (35 jtg/ml)), although in one case asterixis persisted at much lower serum levels. In the two cases of asterixis caused by carbamazepine, the plasma level was 23 and 41 jkmol/l (5.4 and 9.7 jug/ml). Neurotoxic effects of this drug usually appear above 25 urmol/l (6 ,tg/ml) (Reynolds, 1975b) .
OTHER TOXICITY ASSOCIATED WITH DYSKINESIAS
In every case of asterixis reported there were additional signs of cerebellar toxicity in the form of nystagmus and ataxia in all, and dysarthria in most. Mental confusion was also noted in four of the 11 patients described. However, in two of our cases asterixis was the only sign of toxicity when rechallenged with the offending drug (cases 1 and 4).
Similar signs of cerebellar toxicity were noted in the majority of patients with other forms of dyskinesias, but nystagmus was not evident in seven of the 19 patients with orofacial dyskinesias, chorea, or dystonia in whom it was looked for. Ataxia and dysarthria were not apparent in four patients, and in others may well have been due to the dyskinesias rather than to cerebellar dysfunction. Thus, as has recently been recognised for DPH-induced mental changes (Reynolds, 1975a) , dyskinesias may occur with little or no evidence of cerebellar dysfunction. Such toxicity is therefore easily overlooked unless blood levels of the drug are determined. When dyskinesias and mental changes occur together, especially in brain damaged retarded patients, the clinical picture may be mistaken for a progressive degenerative disorder (Logan and Freeman, 1969; Reynolds, 1975a) .
CLINICAL FACTORS RESPONSIBLE FOR ANTICONVULSANT-INDUCED DYSKINESIAS
Apart from the proven association of such dyskinesias with anticonvulsant intoxication, it has been suggested that they appear more readily in epileptics with known cerebral pathology (Logan and Freeman, 1969; Shuttleworth et al., 1974; Ahmad et al., 1975) . While many of the cases reported indeed had neurological deficits in addition to their epilepsy, some have been otherwise normal people. Thus, at least three of our patients (cases 2, 4, and 5) had no other neurological deficit, and asterixis occurred in one patient with tic douloureux (case 3). At present there is insufficient information to decide whether anticonvulsant-induced dyskinesias are more readily provoked in brain-damaged epileptics, but such cerebral pathology is not essential. The age of the patient, type or duration of epilepsy, and the duration of therapy do not appear to play a significant role in the genesis of anticonvulsant-induced dyskinesias.
PHARMACOLOGICAL BASIS OF ANTICONVULSANT-INDUCED DYSKINESIAS
Asterixis Asterixis was originally reported in patients with liver disease (Adams and Foley, 1949) , but is now known to be a common feature of a variety of metabolic and drug-induced encephalopathies (Leavitt and Tyler, 1964) , to which anticonvulsant intoxication must be added. It is not possible to relate any specific neurochemical changes to the induction of asterixis.
Orofacial dyskinesias, limb chorea, and dystonia These abnormalities, caused by intoxication with DPH (but not, apparently, with other anticonvulsants), are very similar to the tardive dyskinesias seen in patients on chronic neuroleptic drug therapy . The tardive dyskinesias produced by neuroleptics most commonly consist of an orofacial dyskinesia which may occur alone but which is often associated with limb chorea and dystonia. The dyskinesia seen in our cases 4 and 5 could easily have been mistaken for neurolepticinduced tardive dyskinesias. This suggests that both DPH and neuroleptic drugs cause dyskinesias by a similar mechanism, but there are, of course, striking differences between the two groups of drugs, both in their therapeutic properties and in their side-effects (Table 3) .
The mechanisms by which neuroleptics cause tardive dyskinesias are not understood. It is currently believed that such dyskinesias (as well as the antipsychotic action of these drugs and the Parkinsonism and akathisia that they produce) are due to their capacity to block cerebral dopamine receptors (Marsden, 1975) . Such an action can be demonstrated by a variety of different animal experiments. DPH has been found to have actions similar to those of neuroleptics in some, but not all, of these animal models (Table 4) . We have also observed a trend towards raised CSF levels of homovanillic acid in drug treated epileptics with 'therapeutic' and toxic blood levels of DPH and phenobarbitone (Chadwick 
